A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients

Leukemia

Volumn 29, Issue 1, 2015, Pages 218-229

  Bae, J ^a,b   Prabhala, R ^a,b,c   Voskertchian, A ^d   Brown, A ^a,b   Maguire, C ^e   Richardson, P ^a,b   Dranoff, G ^a,b   Anderson, K C ^a,b   Munshi, N C ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD137 ANTIGEN; CD138 260 268 PEPTIDE; CS1 239 247 PEPTIDE; GAMMA INTERFERON; LENALIDOMIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; SYNDECAN 1; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; XBP1 SP 367 375 PEPTIDE; XBP1 US 184 192 PEPTIDE; CS1 PEPTIDE; DNA BINDING PROTEIN; EPITOPE; PEPTIDE; REGULATORY FACTOR X TRANSCRIPTION FACTORS; SDC1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MEMORY; MIDDLE AGED; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; PHENOTYPE; SMOLDERING MULTIPLE MYELOMA; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; VERY ELDERLY; CELL PROLIFERATION; CYTOLOGY; DISEASE COURSE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; DISEASE PROGRESSION; DNA-BINDING PROTEINS; EPITOPES; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PEPTIDES; SYNDECAN-1; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS;

EID: 84920666019     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.159     Document Type: Article

References (50)

1. Group TIMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
2. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011; 117: 5573-5581.
3. Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013; 54: 2215-2218.
4. Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res 2013; 19: 985-994.
5. Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: redefining myeloma. Nat Rev Clin Oncol 2012; 9: 494-496.
6. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I-a randomized study. Eur J Haematol 1993; 50: 95-102.
7. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113: 1588-1595.
8. Barlogie B, van Rhee F, Shaughnessy Jr. JD, Epstein J, Yaccoby S, Pineda-Roman M et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008; 112: 3122-3125.
9. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 2007; 20: 597-612.
10. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003; 198: 1753-1757.
11. Kuranda K, Berthon C, Dupont C, Wolowiec D, Leleu X, Polakowska R et al. A subpopulation of malignant CD34 +CD138 +B7-H1 + plasma cells is present in multiple myeloma patients. Exp Hematol 2010; 38: 124-131.
12. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296-304.
13. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE et al. Increased level of both CD4+FOXP3 + regulatory T cells and CD14 + HLA-DRlow myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72: 540-547.
14. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA et al. In vivo peripheral expansion of naive CD4 + CD25high FoxP3 + regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940-3949.
15. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006; 108: 1435-1440.
16. Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol 2012; 2012: 196063.
17. Kabaker K, Shell K, Kaufman HL. Vaccines for colorectal cancer and renal cell carcinoma. Cancer J 2011; 17: 283-293.
18. Rezvani K, de Lavallade H. Vaccination strategies in lymphomas and leukaemias: recent progress. Drugs 2011; 71: 1659-1674.
19. Rousseau C, Ferrer L, Supiot S, Bardiès M, Davodeau F, Faivre-Chauvet A et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol 2012; 33: 679-688.
20. Lonial S, Kaufman J, Laubach J, Richardson P. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther 2013; 13: 1731-1740.
21. Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC et al. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res 2012; 18: 4850-4860.
22. Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011; 117: 1311-1314.
23. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2011; 154: 745-754.
24. Jagannath S, Chanan-Khan AA, Heffner LT. BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in a phase I study in patients with relapsed or relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2010; 116: 3060.
25. Bae J, Carrasco R, Lee AH, Prabhala R, Tai YT, Anderson KC et al. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia 2011; 25: 1610-1619.
26. Bae J, Tai YT, Anderson KC, Munshi NC. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol 2011; 155: 349-361.
27. Bae J, Song W, Smith R, Daley J, Tai YT, Anderson KC et al. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol 2012; 157: 687-701.
28. Zheng Z, Takahashi M, Narita M, Toba K, Liu A, Furukawa T et al. Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha. J Hematother Stem Cell Res 2000; 9: 453-464.
29. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003; 197: 1141-1151.
30. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
31. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012; 11: 1062-1070.
32. Slingluff Jr. CL, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8 + and CD4 + T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009; 15: 7036-7044.
33. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008; 14: 169-177.
34. Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol 2013; 6: 69-82.
35. van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012; 4: 253-268.
36. Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 2012; 18: 1426-1434.
37. Olson JA, Jameson SC. Keeping STATs on memory CD8 + T cells. Immunity 2011; 35: 663-665.
38. Arens R, Schoenberger SP. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol Rev 2010; 235: 190-205.
39. Junker N, Kvistborg P, Køllgaard T, Straten Pt, Andersen MH, Svane IM. Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cell Immunol 2012; 273: 1-9.
40. Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abdulsamad K, Adams SL. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10. Immunol Invest 2008; 37: 315-338.
41. Ye SW, Wang Y, Valmori D, Ayyoub M, Han Y, Xu XL et al. Ex-vivo analysis of CD8 + T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content. J Clin Immunol 2006; 26: 447-456.
42. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666.
43. Viganò S, Perreau M, Pantaleo G, Harari A. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012; 2012: 485781.
44. Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 2001; 293: 248-250.
45. Pepper M, Pagán AJ, Igyártó BZ, Taylor JJ, Jenkins MK. Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. Immunity 2011; 35: 583-595.
46. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z et al. Wnt signaling arrests effector T cell differentiation and generates CD8 + memory stem cells. Nat Med 2009; 15: 808-813.
47. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J et al. Inflammation directs memory precursor and short-lived effector CD8+ T cell fates via the graded expression of T-bet transcription factor. Immunity 2007; 27: 281-295.
48. Kallies A, Xin A, Belz GT, Nutt SL. Blimp-1 transcription factor is required for the differentiation of effector CD8 + T cells and memory responses. Immunity 2009; 31: 283-295.
49. Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol 2012; 2012: 196063.
50. Tucci M1, Stucci S, Strippoli S, Dammacco F, Silvestris F. Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist 2011; 16: 1040-1048.